A recent study identified a Sirtuin 3 (SIRT3)–ATF4 axis required to maintain survival of DLBCL cells, regardless of subtype, by enabling them to optimize amino acid uptake and utilization. The gene discussed is ATF4; the disease is diffuse large B-cell lymphoma.